ATRA Q3'26 Earnings: revenue estimate is 800.00K USD

Atara Biotherapeutics (ATRA) announced the FDA accepted its resubmitted BLA for tabelecleucel, a therapy for EBV+ PTLD. The FDA set a target action date of March 31, 2027. If approved, Atara could receive a $31M milestone payment and royalties. The therapy has Breakthrough and Orphan Drug designations.

Atara Biotherapeutics (ATRA) announced the FDA accepted its resubmitted BLA for tabelecleucel, setting a PDUFA target date of Mar 31, 2027. Approval could result in a $31.0M milestone payment from Pierre Fabre. This follows earlier regulatory setbacks and sets a clear U.S. review timeline.

Atara Biotherapeutics' drug, Tab-cel, has a PDUFA target action date of March 31, 2027, for potential approval as the first U.S. treatment for a post-transplant disease linked to Epstein-Barr virus. The company resubmitted its BLA and awaits FDA review. If approved, Tab-cel would be the first therapy of its kind in the U.S.

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87%

Diebold Nixdorf's stock fell 11.2% to $59.24 after reporting Q3 2026 earnings below expectations. The company missed EPS estimates by 15.7% and lowered its full-year guidance for EPS, EBITDA, and free cash flow, citing revenue mix shifts and cost inflation. The broader market showed little movement, indicating the decline was company-specific.